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ABSTRACT 
Local Delivery Minocycline Gel for the 
 Treatment of Moderate to Severe Periodontitis 
The Advanced Education Program in Periodontology, the University of Minnesota 
 
Background: Local delivery of antimicrobial agents has been used for many years as an 
adjunct to treat periodontal disease. The gel form of minocycline local delivery 
application has an advantage in that it allows multiple sites to be treated with the same 
syringe loaded with minocycline gel when compared to other modalities on the market.  
However, the use of this gel form of minocycline has not been clinically proven effective 
or approved for clinical use in the United States. 
Objectives: The objective of this study was to determine the clinical efficacy of a 2.1% 
minocycline gel as an adjunct to scaling and root planning (SRP) for treating patients 
with moderate to severe periodontitis. The hypothesis for this study is that patients with 
moderate to severe periodontitis would have a statistically significant greater increase in 
clinical attachment (CAL) gain, reduced pocket depth (PD), and reduced bleeding on 
probing (BOP) when SRP  with adjunctive minocycline gel were used when compared to 
patients treated with sham (SRP alone) and vehicle control (SRP+ vehicle without active 
ingredient). 
Material and Methods: Eligible patients (n=59) had at least ten remaining teeth and 
each subject had at least four teeth with pocket depths ≥5 - ≤9 mm with BOP at baseline. 
In addition to baseline, patients were evaluated at three, six and nine months. Enrolled 
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subjects were randomly assigned to one of three groups: 1) root planing therapy only-
sham; 2) root planing therapy and the vehicle control; 3) root planing and minocycline 
gel. The minocycline gel as well as the vehicle control were administered at 2 weeks and 
at the one, three and six-month visits. No mechanical debridement as supportive 
periodontal therapy was performed during this study. 
Results: It was found that in the overall study population the minocycline study group, 
when compared to the sham group, resulted in a greater significant decrease BOP 
(p=0.035) at 3-month, but not when compared to the vehicle control group (p=0.64). In 
sites presenting with the severe form of periodontitis (≥8 mm), there was a statistically 
significant difference between the minocycline gel group and the sham group with 
respect to % BOP reduction at 9-months (p=0.014).  On the other hand, results failed to 
show any other statistically significant difference between the minocycline gel group and 
the sham group with respect to other clinical variables including PD and CAL (p>0.05). 
However, minocycline gel did present with statistically significant differences compared 
to the vehicle control group with respect to the clinical variables.  
Conclusion: The minocycline gel as an adjunct to non-surgical periodontal therapy 
provided a significant favorable clinical effect in decreasing BOP for all moderate to 
severe periodontitis sites following SRP at the 3-month evaluation. In the severe forms of 
periodontitis, minocycline gel had an adjunctive favorable effect at 9-months after SRP 
with respect to %BOP reduction.  
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REVIEW OF THE LITERATURE 
Periodontitis is characterized by the progressive loss of support and clinical 
attachment of teeth. It is known that periodontitis is accompanied by inflammation and 
degradation of the tissues surrounding and supporting the teeth, comprising the gingiva, 
alveolar bone and the periodontal ligament. In periodontitis, the destruction of the 
supporting tissues ultimately may lead to tooth loss. Clinically, periodontitis presents 
with episodes asynchronous, multiple burst with respect to the duration of the disease and 
pattern of periodontal tissue destruction.  The primary etiology of periodontitis is 
bacterial plaque that accumulates on the tooth surface and under the gingival margin. 
This bacterial plaque colonizes and forms an organized mass that can shift from a healthy 
state to pathogenicity. Bacterial composition and the pathogenic potential of plaque can 
vary from individual to individual, tooth to tooth, and site to site, even in the same 
individual. Periodontal pockets harbor plaque over time, and if left untreated they will, in 
a susceptible individual, get deeper and become inaccessible to daily oral hygiene 
procedures.  
It is estimated that at least one third of dentate U.S. adults over the age of 30 have 
periodontitis1. Among periodontitis patients, roughly 22% will clinically present a mild 
form of the disease and 12.6% will clinically present a moderate or severe form. As the 
prevalence of periodontitis increases with age, so does the prevalence and extent of 
attachment loss leading to tooth loss2.   
2 
 
Introduction 
Current evidence supports the fact that periodontitis is a multifactorial chronic 
disease model. These multiple factors influence clinically observable phenotypes at the 
individual patient level. It is established in the literature that periodontal pocket depth 
classification based on severity alone fails to capture important dimensions of an 
individual’s susceptibility to the disease, especially with regard to the complexity of 
managing moderate to severe forms of periodontitis.  
 A review by Wolff and colleagues. presented the ‘risk assessment model’ 
involving the bacterial factor, as well as the environmental and host factors, leading to 
and affecting the phenotypic clinical presentation of periodontitis3. In this model, Wolff 
and his colleagues describe how a potentially pathogenic bacteria may also exist in a 
carrier state which may be compatible with periodontal health. However, if an 
environmental and/or host risk marker that may negatively affect the host’s susceptibility 
enters into the model, then a specific strain of bacteria may shift the bacterial colony to 
pathogenicity and lead to periodontal disease, resulting in loss of attachment. The 
presence or absence of BOP is considered a negative predictor indicator for periodontal 
disease progression. Although the sensitivity of BOP is around 30%, the specificity of 
BOP as a negative predictor for periodontal disease presence was found to be 98% as 
described in a study by Lang and colleagues4. These findings are in agreement with 
previous studies and papers describing the importance of BOP presence or absence as an 
important marker and as a part of the risk assessment for periodontal disease5-8.
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Treatment of Periodontal Disease 
The primary objective of periodontal therapy is to eliminate the inflammatory 
process resulting in periodontal tissue destruction via the host immune response by 
altering the composition of the bacterial ecosystem present within the subgingival plaque. 
Periodontal therapy is composed of both non-surgical and surgical modalities. 
Mechanical debridement is a widely used non-surgical method to control disease 
progression, but it can also be used to alter the periodontal environment to a less 
pathogenic state. This is done by altering bacterial numbers and by modifying the root 
surface to favor periodontal healing. As of today, the ‘gold standard’ of non-surgical 
periodontal therapy involves mechanical scaling and root planing (SRP). SRP is known 
to be clinically effective9-11.  
 
A systematic review assessing the clinical outcomes of non-surgical periodontal 
therapy (SRP) reported overall probing pocket depth (PD) reductions of an average of 
1.45 mm and clinical attachment level (CAL) gain of 0.89 mm following root planing4. 
Similar results were consistently reported across other systematic reviews9,12.  These 
findings can serve as a reference point when assessing the effectiveness of adjunctive 
therapies to non-surgical periodontal therapy and their benefit to the overall clinical 
variable outcomes.  
Retrospective studies reported that untreated periodontal disease causes 0.36 teeth 
to be lost per year, as stated in a study by Becker and co-workers, which followed up on 
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periodontitis patients13. In his study, Becker looked at patients who chose to be left 
untreated for their periodontal condition, patients that were treated and maintained with 
supportive periodontal therapy, and patients who chose to be treated and not maintained. 
Over the 10 year follow up, Becker found that periodontitis was progressive in these 
patients and that periodontitis can clinically present a rapid progression with a 
periodontal breakdown if left untreated. With respect to the type of tooth loss, molars 
were lost most frequently. Overall, there was a difference in annual average tooth loss for 
the different groups of patients. Becker and his colleagues described that patients who 
were in need for periodontal therapy but did not follow through therapy lost 0.36 teeth 
annually compared to periodontally treated patients which were not maintained with 
supportive periodontal therapy having an annual tooth loss of 0.22. On the other hand, 
patients who were periodontally treated and well maintained lost only 0.11 teeth 
annually.  
The gingival crevicular fluid (GCF) represents an interstitial fluid which appears 
in the gingival crevice as a result of a change in the osmotic gradient. This initial, pre-
inflammatory fluid is considered to be a transudate which, upon stimulation, becomes an 
inflammatory exudate14. Any substances that are placed into the periodontal pocket are 
washed out by the GCF, making it difficult for any drug to achieve therapeutic levels and 
to be maintained within the periodontal pocket15-17. In deep pockets with periodontal 
disease, the GCF flow is increased significantly (44 µl/h) compared to shallow healthy 
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pockets (only 1-3 µl/h). This phenomenon may reduce the therapeutic effect of any 
therapeutic agent placed into the periodontal pocket18. 
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Antimicrobial Agents Used in Periodontal Therapy 
Antimicrobials have been used as adjuncts to periodontal therapy for decades to 
achieve an increased level of clinical effectiveness. In order to be considered beneficial 
and effective, antimicrobials should reach the minimal inhibition concentration (MIC) at 
the site itself and should remain for a long enough time to achieve clinical effectiveness. 
Systemic antibiotics used as adjuncts have an advantage in that they have the capability 
to reach across multiple sites at the same time and to decrease either total bacterial count 
or the amount of a specific strain of bacteria, depending on their mode of action. This use 
of systemic antibiotics offers both a more affordable adjunct therapy and a less invasive 
procedure than local delivery agents, but it is more patient dependent. Although there are 
certainly benefits to the use of systemic antibiotics, they cannot replace root planing for 
surface modification and for physically removing plaque19-22 . The disadvantages in using 
systemic antibiotics are the development of antibiotic-resistant strains of bacteria due to 
the higher dependency on patient compliance and the potential for adverse reactions with 
other medications the individual may be on.   
The idea of using antimicrobial agents in a local delivery method as a way to 
boost therapeutic antibiotic doses and concentration in the periodontal pocket was 
introduced by Goodson and co-workers in the late 70’s. An effective locally delivered 
antimicrobial agent is one that is effective against the target microbial flora and one 
which exhibits fewer or no undesirable systemic effects. Local delivery agents do not 
depend on patient compliance. Local delivery agents in the periodontal pocket can attain 
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a 100-fold higher concentration of the antimicrobial agent in subgingival sites than when 
administered systemically, with less potential risk of developing resistant strains and 
super infections. Furthermore, there is a lower risk of adverse systemic reactions.  
 
Kinetics of Drug Release 
Along with its advantages, applying an antimicrobial agent in a local delivery 
system also has its limitations. The GCF washing effect, as well as the high rate of GCF 
turnover, poses a challenge to maintaining the agent inside the periodontal pocket23. The 
percentage of drug that is eliminated per time unit, independent of the concentration, is 
called first-order kinetics. In contrast, zero-order kinetics is the constant amount 
(milligrams, etc.) of drug quantity eliminated per unit of time. When drugs are delivered 
in a controlled release method, the level and time availability of a drug is dependent 
mainly on the removal rate and the rate of release from the carrier device. The ultimate 
challenge with local delivery agents is how to maintain the effective therapeutic range; 
the rate of release of the drug itself, and the rate of the carrier’s absorption or breakdown, 
can affect the efficacy of the drug. A late carrier breakdown will result in a lower amount 
of total drug availability and the concentration necessary to maintain therapeutic levels.  
For drugs administered systemically, the drug concentration in blood plasma 
increases over time until it reaches a concentration peak. The concentration peak is 
followed by a decrease according to the drug’s half-life after reaching a concentration 
plateau within the therapeutic range. Low dosages of systemically delivered drugs may 
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result in less than the necessary therapeutic levels. One of the greatest advantages of 
using a controlled release agent is that it provides an immediate effective dosage, capable 
of rapidly reaching the therapeutic level in a specific site which is maintained within the 
therapeutic range over time utilizing either zero-order kinetic release or sustained release. 
 
Chlorhexidine Local Delivery Antimicrobial Agent Used in Periodontal Therapy 
Chlorhexidine (CHX) is an antiseptic agent that was discovered by scientists who 
were looking for anti-malaria agents, and it has been used for oral application since 1959. 
In modern times, chlorhexidine’s major application objective is the control of dental 
plaque48.  Chlorhexidine gluconate is a cationic bis-biguanide, broad spectrum antiseptic, 
with a positive charge that binds to the negative charge on the bacterial cell wall and 
salivary glycoproteins. By this binding mechanism, CHX interferes with pellicle 
formation and bacterial attachment to the tooth surface, as well as altering the osmotic 
equilibrium which leads to the disruption of bacterial cell integrity. The CHX duration of 
action is prolonged by its ability to be absorbed by oral structures, and then slowly being 
released for up to 24 hours24. 
 Chlorhexidine was studied extensively with respect to a local delivery 
subgingival application and its effects on periodontitis25,26. Khoo and Newman obtained 
direct evidence of an effect against subgingival plaque in terms of reducing proportions 
of spirochetes and motile organisms27,28. A study from the Hebrew University in 
Jerusalem published by Friedman and co-workers looked at chlorhexidine dilacetate in a 
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mode of sustained release to deal with the challenge of the ‘washing effect’ by the GCF29. 
Friedman found that embedded chlorhexidine in polymeric films presented a sustained 
release of the drug over several months.  
Soskolne and colleagues studied the efficacy of a chlorhexidine chip (PerioChip), 
which is composed of CHX in a biodegradable case in a cross-linked hydrolyzed gelatin 
matrix that is released when in serum, urine and GCF media30. Soskolne found that the 
initial peak concentration of chlorhexidine in the GCF was reached as soon as two hours 
post chip insertion, results which were maintained over the next 96 hours. Soskolne also 
reported that the CHX concentration progressively decreased until the study conclusion. 
The results of the study also showed that CHX was not detectable in any of the plasma or 
urine samples at any time point during the study, proving no detectable systemic 
absorption of locally delivered chlorhexidine.  
A split-mouth, single-blind study led by Heasman and colleagues looked at the 
efficacy of local delivery of the ‘PerioChip’ chlorhexidine sustained release agent as an 
adjunct to SRP in periodontitis patients31. Heasman found that only at the six-month 
follow-up was there a difference between the test group using PerioChip chlorhexidine 
adjunct to SRP compared to SRP alone at sites with PD greater than 5 mm at baseline.  
A different clinical trial led by Stabholz and colleagues looked at the efficacy of 
chlorhexidine from an ethyl cellulose-based carrier in a 2-year follow up with a split 
mouth clinical trial comparing the chlorhexidine sustained release adjunct to SRP and 
routine maintenance therapy following SRP32. In this study the results showed that there 
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was a significantly greater pocket depth reduction and attachment level gain compared to 
SRP alone. These results were stable and maintained over a 2-year follow up period. 
With an idea similar to the concept of using PerioChip as an adjunct to SRP 
compared to SRP alone, Jeffcoat and co-workers looked at the clinical variables after 
using a local delivery chlorhexidine chip compared with SRP alone33. In this multi-center 
study, the results demonstrated doubling in the proportion of sites showing a greater 
pocket depth reduction of 2 mm or more from baseline at 9 months in the PerioChip + 
SRP group compared to SRP alone group in sites greater than 5 mm at baseline. Azmak 
and colleagues looked at the effect that the subgingival controlled release of a 
chlorhexidine chip had on the matrix metalloproteinase-8 (MMP-8) levels in the gingival 
crevicular fluid34. Azmak reported results showing that there were significant decreases 
in the GCF MMP-8 levels for the SRP plus PerioChip group compared to SRP alone at 
sites with PD of 6 to 8 mm at baseline.  
On the other hand, Grisi and colleagues reported contradicting findings that the 
PerioChip did not provide any clinical or microbiological adjunct benefit to that achieved 
with conventional scaling and root planing alone in a 9-month clinical trial35. In another 
systematic review paper, PerioChip was compared with other local delivery 
antimicrobials. Addy and colleagues also found contradicting results to previous papers 
and studies that described a statistically significant positive effect of PerioChip on PD 
and CAL36. Addy reported that the CHX chip did not appear as clinically effective as 
more specific antimicrobial drugs such as metronidazole or tetracycline when used as 
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adjuncts to mechanical non-surgical periodontal therapy. Overall, with these 
contradicting reports, PerioChip studies presented inconclusive and contradictory data to 
show definitive favorable and reproducible results in treating periodontitis patients either 
as a sole therapy, or as an adjunct to traditional non-surgical periodontal therapy.  
 
Metronidazole Local Delivery Antimicrobial Agents Used in Periodontal Therapy 
The antimicrobial bactericidal agent metronidazole was found to have a favorable 
effect on the clinical variables of patients presenting with chronic periodontitis37. The 
MIC of metronidazole gel was maintained in the GCF for 24-36 hours. With that concept 
in mind, the gel needed to be redelivered into each pocket at one-week intervals to 
generate positive clinical results. 
 In a paper from the year 2000, a group led by Stelzel looked at the efficacy of 
25% metronidazole dental gel as an adjunctive therapy to SRP38. Fifty-nine patients with 
adult periodontitis were followed for a 9-month period in a split mouth design 
randomized clinical trial. The results showed minor improvement in favor of the 
application of metronidazole gel as an adjunct to SRP compared to the SRP alone control 
group. A separate investigation by Ainamo and colleagues performed a multi-center, 
randomized clinical trial with a split mouth design that compared the monotherapy of 
metronidazole gel to SRP for PD ≥ 5 mm39. Ainamo reported no significant differences 
between the two study groups after 24 weeks. 
  
12 
 
Tetracycline Local Delivery Antimicrobial Agents Used in Periodontal Therapy 
Tetracycline can be produced naturally from a species of Streptomyces or it can 
be derived in a semi-synthetic fashion40. Tetracycline is bacteriostatic antimicrobial agent 
effective against rapidly multiplying bacteria and gram-positive bacteria. Tetracycline 
possesses unique non-antibacterial characteristics such as collagenase inhibition, 
inhibition of neutrophil chemotaxis, anti-inflammatory effects, inhibition of microbial 
attachment, and root surface conditioning 41. The antibacterial mechanism of tetracycline 
is the inhibition of protein synthesis in prokaryotes by binding to 30S ribosomes in both 
gram-negative and gram-positive microorganisms. Tetracycline acts by preventing 
attachment of aminoacyl tRNA to the RNA-ribosome complex and it simultaneously 
inhibits other steps of bacterial protein synthesis, providing a wide spectrum of 
bacteriostatic activity. 
In one of his earlier studies from the 70’s, Goodson and co-workers used 
tetracycline filled hollow fibers placed in the gingival crevice to treat periodontitis42,43. 
Results of Goodson’s studies showed that the tetracycline fibers had “a dramatic effect on 
both the periodontal subgingival microflora and on the clinical manifestations of 
periodontal disease”. The down side of these fibers was that they allowed only a minimal 
control of drug release as the majority (95%) of the drug was released in the first 2 hours. 
Drug leakage also negatively affected the therapeutic range of these tetracycline fibers.   
Michalowicz and colleagues reviewed periodontal disease recurrence at 3-12 
months following various treatment modalities compared to controlled release 
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tetracycline fibers as adjuncts to SRP 44. Michalowicz and colleagues found that the sites 
treated with tetracycline fibers had significantly less disease recurrence (4%) than 
tetracycline fiber therapy as a sole therapy with no SRP. Maze and co-workers studied a 
tetracycline-controlled release material following a single application of 35% tetracycline 
hydrochloride in a glycolic acid gel in  healthy adult volunteers45. The biodegradable gel 
was found to be safe and the effective range of bacteriostatic activity against putative 
periodontopathogens was in the 2-10 µg/ml range. This range had a significant 
antimicrobial efficacy lasting up to 8 days. Friedsen and colleagues studied the efficacy 
of locally delivered tetracycline strips administered in conjunction with root planing 
compared to root planing alone46. The author reported a significant positive PD and BOP 
reduction compared to baseline in the test group. The anti-collagenase activity of 
tetracycline was reported in several animal studies47-53. Local delivery tetracycline also 
inhibited polymorphonuclear leukocyte collagenase activity in vitro; this suggests that 
locally delivered tetracycline fibers placed into individual periodontal pockets could 
maintain tetracycline concentration in the GCF, which would then potentially inhibit 
periodontal tissue breakdown by tetracycline’s anti-collagenase activity. Tetracyclines 
may also have an effect on members of the microbial community that have a lower MIC 
than other putative pathogens. 
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Doxycycline Local Delivery Antimicrobial Agents Used in Periodontal Therapy 
Doxycycline was patented in 1957 and has been commercially used since 1967. 
Doxycycline, as is the case for other tetracycline members, is bacteriostatic and it works 
by preventing bacteria from reproducing through the inhibition of protein synthesis. One 
of its differences from tetracycline is that doxycycline enters the duodenum for 
absorption more than tetracycline compounds due to its unstable state at a lower pH. 
 The local delivery doxycycline commercially available today is Atridox. Atridox 
is a doxycycline polymer which is an injectable polymer matrix containing 8.5% 
doxycycline hyclate. Slots and colleagues described how periodontal pathogens have 
increased antimicrobial susceptibility to doxycycline when compared to tetracycline and 
other antibiotics 54. In a 6-month, randomized, multi-center, placebo-controlled study of 
the efficacy of a combination of systemically delivered doxycycline hyclate 20 mg bid 
plus locally delivered doxycycline hyclate gel (10%) in PDs ≥5 mm as an adjunct to SRP 
was compared to SRP plus placebo55. Clinical variable outcomes showed that for PD’s ≥4 
- 6 mm, the combination therapy provided significant improvement over the control 
group for both PD and CAL. 
Results of another clinical trial looking at the efficacy of locally delivered 
doxycycline in a gel form reported promising findings56. In this study, there were 
significant reductions in the number of anaerobic bacteria lasting at least 21 days, which 
then returned to baseline by 91 days. These findings provided further evidence for a 
short-term antimicrobial effect with local delivery. Overall, doxycycline gel significantly 
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reduced the anaerobic population in plaque, but it did not result in a change in either the 
number of resistant bacteria present or the acquisition of antibiotic resistance.  
 Eickolz and co-workers used a 15% doxycycline gel as an adjunct to SRP and 
assessed the relative attachment level gain and pocket depth reduction compared to SRP 
alone in severe periodontitis patients (PD 7 mm)57. It was concluded in this paper that 
adjunctive topical subgingival application had favorable effects with respect to 
attachment level gain and PD reduction compared to SRP alone. In a multi-center study, 
the efficacy and safety of doxycycline hyclate (8.5%) delivered through a biodegradable 
polymer as the sole therapy in patients with moderate to severe periodontitis was 
compared to SRP alone58. The results of this study demonstrated a mean 9-month CAL 
gain of 0.8 mm for the doxycycline group and 0.7 mm for the SRP group in one study 
center, and 0.8 mm and 0.9 mm respectively in the other center. With respect to PD 
reduction, the results of this study showed a mean PD reduction of 1.1 mm for the 
doxycycline group and 0.9 mm for the SRP group in one center, and 1.3 mm for both the 
test and control group in the second center. The results of this study suggested that 
doxycycline as a sole therapy has a similar clinical efficacy and a clinical equivalence to 
SRP. 
A small split mouth study by Martorelli and colleagues of 11 individuals with 
type I diabetes with baseline PD greater or equal to 5 mm compared the outcomes of SRP 
only to doxycycline gel plus SRP and SRP plus placebo gel59. Martorelli found there was 
greater PD reduction and CAL gain in the doxycycline gel group than in the control 
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group. The authors concluded there was an overall clinical benefit of using the adjunctive 
doxycycline in diabetes mellitus type I patients with chronic periodontitis. 
 
Minocycline Local Delivery Antimicrobial Agents Used in Periodontal Therapy 
Minocycline is a semi-synthetic antimicrobial agent from the tetracycline family. 
A number of studies in the literature advocate minocycline as a more effective 
antibacterial agent than tetracycline in its inhibition of gram-negative facultative 
anaerobes, and that minocycline has a combined effect of increased absorption and a 
higher concentration in the GCF when administered systemically. These characteristics 
make minocycline a more preferable antibiotic in a local delivery system with potential 
for better clinical efficacy in the treatment of periodontal infections. 
Clinically, with respect to periodontitis, a review by Van der Kerckhover focused 
on minocycline ointment application as an adjunct to SRP60. It was concluded in the 
review that minocycline ointment had a positive significant result in reducing bacterial 
populations and in eliminating motile organisms. The efficacy of 2% minocycline 
ointment was evaluated by Van Steenberghe and co-workers in a randomized clinical trial 
in individuals exhibiting moderate to severe periodontitis61. In this study, the authors 
evaluated the antimicrobial activity of minocycline against A. actinomyctemecomitans, P. 
intermedia, and P. gingivalis which are known to be major periodontal pathogens. Van 
Steenberghe and co-workers found that in pocket depths greater than or equal to 5 mm 
with CAL loss of greater than or equal to 3 mm at baseline, there was a clinically 
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favorable response to minocycline ointment. Probing depths were reduced at 42% of the 
test sites (SRP+ 2% minocycline ointment), compared to 28% reduction of the control 
sites (SRP only).  
A different local delivery system of minocycline was introduced by Jones and 
colleagues62. In this study, Jones and colleagues looked at the efficacy of a minocycline 
periodontal powder microencapsulated in a biodegradable polymer, poly glycolide-co-dl-
lactide, in periodontitis sites as an adjunct to SRP. The results of this study showed that 
the prevalence of P. gingivalis and P. intermedia decreased significantly when the 
microencapsulated minocycline microspheres were used as an adjunct to SRP in sites 
with greater than or equal to 5 mm pocket depths.  
A similar study by Williams and co-workers looked at the minocycline 
microspheres delivery system as a sustained delivery mechanism to treat sites with 6 to 9 
mm pocket depths exhibiting BOP63. In this study, three parallel treatments: SRP alone, 
SRP and a vehicle control, and SRP with the minocycline microspheres; were put to the 
test in moderate to advanced periodontitis sites. The group treated with minocycline 
microspheres showed substantially greater probing depth reduction than either SRP alone 
or the SRP and the vehicle control. The results showed that clinical efficacy reached the 
level of significance in as early as one month into the study. This level was reported to be 
maintained throughout the trial and was independent of patient smoking status, age, 
gender, or baseline disease level64. Van Dyke and colleagues in a series of studies, also 
found substantially greater reductions in PD and CAL gain at each post-operative time 
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point in the group where minocycline microspheres were used as an adjunct to SRP, 
compared to SRP alone65,66.  
McColland and co-workers compared local delivery of 2% minocycline gel to 
conventional subgingival debridement as part of a supportive periodontal therapy 
maintenance program67. The results presented in this pilot study failed to show a 
significant difference between minocycline gel as a sole therapy and periodontal non-
surgical therapy alone. Interestingly, in this study, the prevalence of P. gingivalis, T. 
forsythia, T. denticola, A. actinomycetemcomitans, P. intermedia, and P. nigrescens 
remained similar for both study groups. This further emphasizes the importance of 
mechanical debridement as an essential part of periodontal therapy.   
A recent pilot study, comparing the effects of antimicrobial photodynamic therapy 
and local administration of minocycline on clinical, microbiological and inflammatory 
markers of periodontal pockets, was conducted in Japan68. The results of this study 
showed that minocycline administered locally had improved clinical, microbiological, 
and crevicular cytokine levels in the periodontal pocket. However, photodynamic therapy 
alone did not show any beneficial clinical effects. In this study, local delivery 
minocycline had shown a significant decrease in scores for the clinical outcomes of 
bacterial counts, as well as pro-inflammatory cytokines, such as interleukin 1.  
With similar objectives in mind, but with contradictory results, a study published 
by Tabenski and colleagues looked at biodegradable minocycline microspheres compared 
to photodynamic therapy as an adjunct to SRP69. This study presented results with 
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significant improvements in both clinical and microbiological parameters, but the study 
results did not differ between study groups in a statistically significant manner. It was 
noted then that efficacy of SRP did not seem to be improved by the local delivery of 
minocycline microspheres, nor by photodynamic therapy with respect to periodontal 
clinical variable outcomes. 
Inflammatory processes around dental implants can result in the loss of 
supporting bone to such an extent that it could lead to implant failure. Renvert and 
colleagues assessed the clinical and microbiologic outcomes of repeated local delivery of 
1mg of minocycline microspheres around implants exhibiting peri-implant inflammation, 
as compared to chlorhexidine gel70.  Thirty-two subjects with at least one implant with 
PD ≥ 4 mm, combined with bleeding and or exudate upon probing and the presence of 
putative pathogenic bacteria suggestive of peri-implant inflammation, were included in 
the study. The use of local delivery minocycline resulted in a significant improvement in 
probing depths compared to chlorhexidine gel. For the deepest sites of the minocycline 
treated implants, the mean probing depth reduction was 0.6 mm at 12 months.  
Generally, tobacco has an adverse effect on the healing of periodontitis and is a 
strong modifiable risk factor and predictor of future disease. There is strong scientific 
evidence that smokers are 2.7 times more likely to have periodontal disease than non-
smokers71. Tobacco-use has an overall negative effect on blood vessels and is an overall 
tissue irritant, which leads to a delay in tissue healing. Heavy smoking (>10 cigarettes per 
day) has been associated with an increased rate of disease progression. Smoking or 
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tobacco-use status represents a key parameter in the risk assessment for an individual to 
develop severe periodontitis and therefore makes the smoking population of interest for 
periodontal research72-78.  
Paquette and colleagues looked at local delivery of minocycline microspheres in 
tobacco smokers exhibiting clinical signs of moderate to severe periodontitis79.  At 9-
months, smokers treated with SRP and adjunctive minocycline microspheres exhibited a 
mean pocket depth reduction of 1.19 mm from baseline, compared to 0.90 mm for 
smokers treated with SRP only. This suggests an additional benefit of local delivery 
minocycline in smokers with moderate to severe periodontitis. A more recent systematic 
review addressing whether the use of local or systemic antimicrobials would improve 
clinical results of non-surgical periodontal therapy for smokers with chronic 
periodontitis80. The meta-analysis resulted in a support of use of adjunctive local 
antimicrobials in a smoking population exhibiting chronic periodontitis. The local 
delivery of antimicrobials resulted in a superior clinical response with respect to PD 
reduction and CAL gain when compared to systemic antimicrobials as adjuncts to SRP. 
 
Statement of the Problem 
Non-surgical periodontal therapy provides limited clinical improvement in 
individuals with moderate to severe periodontitis. The use of adjunctive systemic 
antibiotics with non-surgical periodontal therapy has been known to be effective for 
many years. Systemic administration of antibiotics does add to improvement in clinical 
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variables, but it may cause undesirable adverse effects such as the development of 
resistant bacterial strains, yeast superinfection, and gastro-intestinal upset. Also, in 
patients that are on other systemic medications, there is always a potential for a cross 
adverse reaction. Moreover, systemically administered antibiotics have the additional 
challenge of keeping a sustained therapeutic concentration in the periodontal pocket. 
Local delivery agents, however, offer the use of a lesser dosage of the drug with a more 
potent concentration at the site of treatment along with a minimal risk of a systemic 
adverse effect. 
 
Rationale for the Study 
The purpose of this study is to test the clinical efficacy of a gel form of 
minocycline for local delivery in treating individuals with moderate to severe 
periodontitis. A single syringe of the gel allows multiple periodontal pockets to be filled 
quickly, minimizing treatment time, discomfort to the patient, and expenses to both 
dentist and patient when compared to the minocycline microspheres. Owing to the gel 
nature of the minocycline formulation, pockets are dosed based on their size allowing for 
flexibility with respect to the number of sites treated and the amount of locally delivered 
agent applied. The flexibility of this minocycline local delivery agent can accommodate 
for differences in the physical and anatomical characteristics of the periodontal pocket.  
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Hypothesis  
The hypothesis for this study is that individuals who have clinically exhibiting 
sites with moderate to severe periodontitis will benefit from treatment with local delivery 
minocycline gel as an adjunct to SRP. The use of minocycline gel as an adjunct therapy 
at these sites will result in a statistically significant reduced PD, reduced BOP and 
increase in CAL gain, when compared to patients treated with a SRP alone (sham) and 
vehicle control (SRP+ vehicle without active ingredient). 
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MATERIAL AND METHODS 
Study Subject Population 
Fifty-nine subjects from the University of Minnesota that met the inclusion 
criteria were included in our study. A selection eligibility criterion was that individuals 
had to present with moderate to severe chronic periodontitis at baseline (5 - 9 mm). 
The subject inclusion and exclusion criteria are shown below. 
Inclusion Criteria 
1. Patients had to be 18 years of age or older. 
2. Patients had to have read, understood, and signed a consent form. 
3. Patients had to be able and willing to follow study procedures and instructions. 
4. Patients had to have moderate to severe periodontitis with at least 10 remaining 
teeth, out of which at least four teeth had pocket depths of ≥5 mm and ≤9 mm 
with bleeding on probing in these pockets. 
Exclusion Criteria 
1. Patients who had periodontal therapy, surgical or non-surgical, within 6 months 
prior to enrollment were not eligible. 
2. Patients who had clinically significant or unstable medical diseases which might 
compromise healing, such as diabetes mellitus, hepatic insufficiency of any 
degree, connective tissue disorders, or who were under treatment where the 
medication may affect healing (e.g., cancer chemotherapy) were not eligible. 
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3. Patients with a heart murmur, history of rheumatic fever, valvular disease or 
artificial heart valves, prosthetic joint replacement, or any other condition 
requiring antibiotic prophylaxis prior to dental appointments were not eligible. 
4. Patients who had been treated with oral antibiotics within 3 months prior to 
enrollment were not eligible. 
5. Patients treated with medications known or suspected to affect periodontal status, 
including cyclosporine, warfarin, non-steroidal anti-inflammatory drugs, 
phenytoin, or calcium antagonists, within 1 month of screening were not eligible. 
Selective use of daily low dose aspirin was permitted in patients who were 
eligible. 
6. Patients who were pregnant, as determined by a positive urine test, or patients 
who were lactating were not eligible. 
7. Female patients who were of childbearing age, except those who were using a 
hormonal barrier method of birth control, were not eligible. 
8. Patients with an allergy to tetracycline or reported serious adverse reactions to 
minocycline were not eligible. 
9. Patients with severe dental disease including caries or any condition likely to 
require antibiotic treatment during the trial and/or severe untreated dental disease 
requiring extensive restorative or surgical treatment during the trial were not 
eligible. 
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10. Patients with active infections such as HIV, hepatitis, or tuberculosis were not 
eligible. 
11. Patients under treatment for cancer, type IV heart disease, or end stage renal 
disease were not eligible 
12. Patients who had taken an investigational drug within 30 days of enrollment were 
not eligible. 
13.  Patients requiring anticoagulation therapy of any type for any reason were not 
eligible. 
14. Patients treated with oral retinoid medications for skin conditions were not 
eligible. 
15. Teeth with pockets surrounding a tooth which had root canal treatment were not 
eligible. 
16. Teeth with pockets in close proximity to a dental appliance were not eligible. 
17. Teeth with pockets at the gingival border of an implant were not eligible. 
18. Patients with localized aggressive periodontitis were not eligible. 
 
Sham Control, Vehicle Control Minocycline Gel Formulation  
Sham control was administered in the same manner as the other treatment groups. 
An empty syringe was used to mimic the application of the minocycline gel after 
completion of SRP at baseline. 
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Vehicle control treatment was the administration of the gel without the active 
minocycline medication after completion of SRP at baseline.  
Minocycline gel (active antimicrobial agent) is a yellow-colored gel containing 
minocycline hydrochloride, together with hydroxythelcellulose, magnesium chloride, 
compolymer of actylates and methacrylates, triacetin and glycerol. The minocycline 
hydrochloride is equivalent to 2.1% minocycline hydrochloride, which is equivalent to 
10.5 mg minocycline in a 500 mg gel carrier. It was supplied in a disposable 
polypropylene applicator.  
 
Study Timeline and Procedures  
Study timeline and procedures completed for each subject in this study are shown 
in Table 1. At the screening visit, full mouth CAL and PD measurements were recorded, 
and the subjects were then randomly assigned to one of the three study groups: sham, 
vehicle control and minocycline gel. The dental operators were periodontists who 
performed scaling and root planing and administered one of the three different treatment 
modalities to each patient at baseline, 14 days, and at months 1, 3 and 6. There was at 
least one trained and standardized operator responsible for all aspects of the dental and 
medical management of patients. Dental examiners for this study were trained and 
calibrated and were not the same individuals as the dentist providing therapy. Dental 
examiners were kept blinded to the patient treatment assignments and were not present at 
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the time of treatment. Dental examiners were responsible for all clinical evaluations 
including measurements of PD, CAL and the BOP assessment. 
 
Study Groups; Sham Control, Vehicle Control and Minocycline Gel  
 Group 1 (SRP + sham) had SRP at baseline plus sham treatment with an empty 
syringe. Group 2 (SRP + vehicle control) and group 3 (SRP + Minocycline gel) had SRP 
at baseline plus the administration of the vehicle control or the minocycline gel, 
respectively. After bleeding diminished following SRP, each treatment site was 
thoroughly rinsed with water, air dried, and isolated with cotton rolls. For group 1 
patients (sham), the tip of an empty syringe was applied to the gingival margin as the 
plunger was depressed into the pocket simulating the application of the gel. For patients 
of the other two study groups, the tip of the syringe used to dispense the vehicle control 
or minocycline gel was inserted subgingivally at the treatment sites to the base of the 
pockets. The pocket was slowly filled drawing the tip of the dispenser coronally.  
The syringes, whether containing the vehicle control or the minocycline gel, 
contained adequate material to fill multiple sites and there was the same quantity of gel 
(500 mg) in each syringe. The minocycline gel syringe contained 10.5 mg of minocycline 
in 500 mg gel which could be used to treat multiple pockets in the same patient. The use 
of a periodontal dressing or any other tissue adhesive was not permitted with any patient. 
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Demographic Data and Tobacco-Use 
Demographic data and tobacco-use for enrolled subjects at the screening 
appointment are shown in Table 2. Each patient’s birth date, gender, ethnicity and 
smoking status was recorded. Previous periodontal therapy information was also 
collected and recorded. Medical histories were obtained at each visit from all patients, as 
well as current medication and the type, dose, and duration of use. Patient vital signs 
were measured at baseline and at the final visit, including oral temperature, pulse and 
blood pressure. 
 
Clinical Measurements 
At each study visit (screening, baseline, day four, day fourteen, and months three, six 
and nine), a clinical evaluation of the patients extra and intra-oral structures was 
performed. A clinical examination of the face, lymph nodes, lips, buccal mucosa, tongue, 
hard and soft palate, gingiva, floor of the mouth, edentulous ridges and teeth was 
performed. Abnormal findings were described and recorded, noting location, size, onset, 
and associated symptoms. The periodontal clinical assessment included pocket depth, 
CAL, BOP, and recession. All periodontal probing measures were rounded to the lowest 
mm. The following clinical parameters were measured: 
1. Pocket depth (PD), defined as the distance in mm from the gingival margin to the 
base of the sulcus/pockets on six surfaces/tooth, except for third molars.  
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2. Recession, defined as the distance in mm from the gingival margin to the CEJ. If 
the gingival margin was apical to the CEJ, it was given a negative value. 
3. Bleeding on probing (BOP), defined as the presence or absence of bleeding on 
probing as recorded 10 seconds after probing of each quadrant. 
4. Clinical attachment level (CAL), defined as the calculated difference between PD 
and the distance from the gingival margin to the CEJ. 
The time frame for each patient to complete their scheduled visits is shown in the 
illustration on the following page. 
 
Calibration of Clinical Examiners  
Calibration of examiners and standardization of all operators occurred at a time 
prior to initiation of the study. All examiners were required to obtain a high level of 
reproducibility. Clinical parameters were measured using a University of North Carolina 
manual periodontal probe. Six sites per tooth were assessed: mesio-buccal, buccal, 
distobuccal, mesio-lingual, lingual, and distolingual.  
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Timeframe for Each Patient to Complete Scheduled Visits 
Visit Time window 
Baseline Within 4 days of scheduling, within 30 days of screening 
Four day visit Within 2-6 days of baseline treatment 
Two week visit 14 days +/- 2 days from baseline 
Four week visit 30 days +/- 5 days from baseline 
Three-month visit 90 days +/- 14 days from baseline 
Six-month visit 180 days +/- 14 days from baseline 
Nine-month visit 270 days +/- 14 days from baseline 
 
Clinical Variable Outcomes 
The primary objective of this study was to determine the adjunctive clinical 
effects of minocycline gel, when compared to the two control groups, with respect to the 
CAL, BOP, and PD levels. Sites exhibiting a PD increase of 3 mm or more between visits 
were identified as ‘rescue sites’. These rescue sites were treated locally by SRP and other 
therapy as determined necessary by the study periodontist. Rescue sites were 
discontinued from the study in terms of the primary endpoint if the breakdown occurred 
in a treatment site. The last PD value recorded before the breakdown was used in the 
primary objective calculations.  
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Statistical Analysis 
Descriptive statistics were used to compare the baseline characteristics of patients 
by treatment group. Continuous measures were summarized with means and standard 
errors (SEs), and comparisons between treatment groups were made using one-way 
analysis of variance, which is analogous to the two-sample t-test for more than two 
groups. Categorical measures were summarized with counts and percentages, and 
comparisons between treatment groups were made using Fisher’s exact test. Similar 
comparisons by treatment group of the clinical outcomes at baseline (PD, CAL, and 
percent BOP) were made. 
To address the primary research question, PD, CAL, and percent BOP were compared 
between treatment groups at each follow-up visit (three, six, and nine months post-
baseline). Two comparisons were considered: comparison of the clinical measure at 
follow-up between treatment groups and comparison of the changes since baseline in the 
clinical measure. Additionally, the percentages of sites PDs which improved by 2 or 3 
mm were analyzed. The responses within treatment groups were summarized using the 
mean and SE. Comparisons across groups were performed using a one-way analysis of 
variance. 
In all analyses, the clinical outcomes were analyzed at the patient level. That is, for each 
patient, outcomes were averaged across sites to obtain the patient-level measurement. 
In addition to comparisons by treatment group for all patients, subgroup analyses were 
performed on the basis of baseline PD. The first subgroup consisted only of sites with 
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baseline PD of ≥5 mm and ≤7 mm and the second subgroup consisted only of sites with 
baseline PD of ≥8 mm and ≤9 mm. For these subgroup analyses, the same patient-level 
averaging was performing using those sites with the appropriate baseline PDs.  
p-values less than 0.05 were considered statistically significant. No formal corrections 
were made for the testing of multiple outcomes. 
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RESULTS 
Demographic Variables 
The demographic data and tobacco-use for enrolled subjects collected at the 
screening appointment is shown in Table 2. There were of 59 subjects (sham-n=19, 
vehicle control-n=20, minocycline gel-n=20) enrolled in this clinical trial, with 58 
subjects completing the study. There were no statistically significant differences (P > 
0.05) between the three study groups with respect to demographic variables (gender, age, 
race nor tobacco-use) at the screening appointment. 
 
Clinical variables 
Mean clinical variables for all sites evaluated (≥5 mm) in patients for each of the 
three study groups at baseline are shown in Table 3. There were no statistically 
significant differences between the groups (p > 0.05). For the primary outcome variable 
of PD; the sham, vehicle control and minocycline gel groups had PDs of 5.82 mm, 5.65 
mm, and 5.68 mm, respectively at baseline. 
Mean clinical variables for all patients and the change in clinical variables from 
baseline at 3 months are presented in Table 4. There was a statistically significant 
difference between the study groups with respect to %BOP reduction (p=0.042). With 
respect to the other clinical variables listed, there were no statistically significant 
differences (p>0.05). 
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 Mean clinical variables for all subjects and the changes in clinical variables from 
baseline at 6 months are presented in Table 5. There were no statistically significant 
differences between the groups with respect to all clinical variable outcomes at this time 
point of the study. The %BOP reduction that was statistically significantly different 
between the study groups at the 3-month time point was no longer significantly different 
at the 6-month time point. 
Mean clinical variables for all subjects and the changes in clinical variables from 
baseline at 9 months are presented in in Table 6. There were statistically significant 
differences with respect to %BOP and %BOP reduction from baseline (p=0.03 and 
p=0.03, respectively). Again, the minocycline gel group had the lowest %BOP levels 
(32.50%) compared to both the sham group (40.84%) as well as compared to the vehicle 
control group (49.63%). Moreover, the minocycline gel group had the greatest %BOP 
reduction (62.95%) compared to the sham group (52.35%) and the vehicle control group 
(46.32%).  
 
Baseline PD ≥5 - ≤7 mm 
Mean clinical variables for patients with PDs 5 - ≤7 mm at baseline are 
presented in Table 7. There were no statistically significant differences with respect to 
PD, CAL and BOP (p>0.05). Similarly, clinical variables at 3 months (Table 8) and 6 
months (Table 9) did not yield any statistically significant differences for the mean 
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clinical variables and mean clinical variable change from baseline for the subjects 
enrolled in each of the three study groups with baseline PDs ≥5 -≤7 mm.  
Mean clinical variables and clinical variable changes at nine months for subjects 
with baseline PDs ≥5 - ≤7 mm is presented in Table 10. For the clinical variable 
outcomes, there was a statistically significant differences between the study groups with 
respect to %BOP (p=0.05) and a trend towards statistically significant differences in 
%BOP reduction from baseline (p=0.06). At the 9-month time point, the minocycline 
group had the least %BOP (32.35%) compared to the sham group (39.39%) and the 
vehicle control (48.25%). The %BOP reduction at 9 months was greatest in the 
minocycline gel group compared to the sham and vehicle control groups (62.85%, 
54.40%, 47.83%), respectively. 
 
Baseline PD ≥8 mm 
Demographics and tobacco-use in each study group for patients with PDs 8 mm 
at baseline are presented in Table 11. Overall, there were fewer patients in each study 
group who had sites with baseline PDs of 8-9 mm. Ten subjects in the sham control 
group, ten subjects in the vehicle control group, and thirteen subjects in the minocycline 
gel group had at least one site with a PD of 8-9 mm at baseline. No statistically 
significant differences were found between the different study groups with respect to the 
demographic variables at baseline (p>0.05). 
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 Mean clinical variables for subjects with PDs ≥8 mm at baseline are presented in 
Table 12. There was a statistically significant difference between the groups with respect 
to the clinical attachment levels noted for these sites. CAL baseline level differences for 
the minocycline gel group (7.02 mm) compared to the sham (8.06 mm) and the vehicle 
control (6.71 mm) groups were noted to be statistically significant (p < 0.05).  
Mean clinical variables and clinical variable changes at three months from 
baseline for subjects with PDs ≥8 mm are presented in Table 13. There were no 
statistically significant differences with respect to the different clinical variables 
(p>0.05). The mean clinical variables and clinical variable changes at six months from 
baseline for subjects with PDs ≥8 mm is presented in Table 14. With respect to %BOP 
reduction from baseline, there was a trend towards a statistically significance difference 
(p=0.06) between the groups at the 6-month visit, where the minocycline gel group 
(59.07%) showed more %BOP reduction compared to the sham group (41.61%) and to 
the vehicle control (17.02%). Also, at 6 months there was a statistically significant 
difference between the different study groups with respect to the percentage of sites that 
improved by 3 mm (p=0.02): the minocycline gel group (71.70%) had the greatest 
percent of PD reduction by 3mm compared to the sham (40.07%) and to the vehicle 
control group (30.36%).  
Mean clinical variables and clinical variable changes at 9 months from baseline 
for subjects with PDs of 8 mm are presented in Table 15. There was a statistically 
significant difference between the different study groups with respect multiple clinical 
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variables, including PD, CAL, and BOP levels. A the 9-month visit, the minocycline 
group had a mean PD level of 4.87 mm, compared to the sham group (5.99 mm) and the 
vehicle control (6.19 mm) group, (p=0.03). With respect to PD reduction, the 
minocycline group had a 3.27 mm PD reduction compared to the sham (2.34 mm) and the 
vehicle control (1.88 mm) groups, (p=0.03). With respect to CAL gain, there was also a 
statistically significant difference at 9 months between the study groups: the minocycline 
group had 2.71 mm of CAL gain, compared to the sham (2.18 mm) and the vehicle 
control (1.35 mm) groups, (p=0.017). The %BOP, as a clinical variable for this study, 
demonstrated a statistically significant difference between the study groups. Again, the 
minocycline group had 36.81% BOP compared to the sham (73.95%) and the vehicle 
control (68.78%) groups, (p=0.04). Moreover, %BOP reduction at 9 months showed a 
statistically significant differences between the different study groups. The minocycline 
gel group had a 63.19% BOP reduction compared to the sham (17.12%) and the vehicle 
control (21.96 %) groups, (p=0.05). Another clinical variable that yielded statistically 
significant differences between the study groups was the % of sites to have improve PDs 
by 3 mm. The minocycline gel group had 62.91% of sites that were reduced at the nine 
month visit by 3 mm or more, compared to the sham (33.8%) and the vehicle control 
(21.43%) groups, (p=0.03). 
 The p-values intragroup analysis for statistically significant findings of the 
various clinical variables and clinical variable changes are presented in Table 16. With 
respect to %BOP, at 3 months there was a statistically significant difference between the 
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minocycline and the sham groups (p=0.03) for both moderate and severe periodontitis 
sites grouped together, favoring the minocycline gel group. At 9 months the %BOP was 
statistically significant only between the minocycline gel and the vehicle control groups, 
again for both moderate and severe periodontitis sites grouped together (p=0.02). 
Regarding %BOP reduction from baseline, for all sites there was a statistically significant 
difference between the minocycline gel and the vehicle control groups (p=0.02). With 
respect to the percentage of sites that had PD levels improved by 2 mm was also 
evaluated, there was a statistically significant difference between the minocycline gel and 
the vehicle control groups for sites ≥8 mm at nine months from baseline (p=0.02). 
Similarly, PD reduction for sites ≥8 mm at nine months from baseline was statistically 
significantly different for the minocycline gel group as compared to the vehicle control 
group, favoring the minocycline gel group (p=0.03). With respect to CAL gain, there was 
a statistically significant difference at 9 months from baseline between the minocycline 
and the vehicle control groups, favoring the minocycline gel group (p=0.01). The %BOP 
reduction was statistically significantly different for sites ≥8 mm at 9 months from 
baseline between the minocycline and the sham groups (p=0.02 and p=0.14, 
respectively), favoring the minocycline group. Lastly, for the percentage of sites that 
improved by 3 mm from baseline of sites ≥8 mm, there was a statistically significant 
difference only between the minocycline group compared to the vehicle control group, 
again favoring the minocycline group (p=0.03). 
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DISCUSSION 
 
The aim of this randomized control clinical trial was to determine the efficacy of locally 
delivered minocycline gel as an adjunct to SRP in moderate to severe forms of chronic 
periodontitis. In this study, all three study groups were well randomized with no 
statistically significant differences between the study groups at baseline with respect to 
demographics, clinical variables, or tobacco-use duration and amount. This study was 
originally a part of a multi-center research project. This thesis is a description and 
analysis of the data and findings from a portion of the patients evaluated at the University 
of Minnesota Clinical Research Center.  
Unfortunately, we do not have the data from the other study centers in order to 
use the power analysis calculated for this study. The fact that we have only part of the 
data with a limited number of subjects and not the full power intended for this multi-
center study should be noted and disclosed in advance. That being said, we can still 
extract trends and, even in this limited group of subjects, detect statistically significant 
differences between SRP and SRP + minocycline gel therapy. The results of this study 
can serve as a pilot study for future investigations of this adjunctive periodontal therapy 
modality. 
Overall, fifty-nine subjects were enrolled in the study. Fifty-eight subjects 
completed the entire protocol and were followed for 9 months. A total of 658 teeth with 
1,464 sites were evaluated at baseline which had PDs ranging from ≥5 mm to ≤9 mm. 
When study subjects exhibited a clinical manifestation of moderate to severe 
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periodontitis, there was a statistically significant difference in favor of the minocycline 
gel group compared to SRP alone (Sham group) with respect to %BOP at the 3-month 
time point (p=0.04). These findings support our hypothesis that sites with moderate to 
severe periodontitis would benefit from treatment with locally delivered minocycline gel 
as an adjunct to non-surgical periodontal therapy. The reduction in %BOP at the 3-month 
visit can serve as support for the use of the minocycline gel as an adjunct to non-surgical 
periodontal therapy with respect to slowing and positively altering periodontal disease 
progression. This may indicate and support the use of minocycline gel as part of a 
supportive periodontal therapy program for moderate to severe periodontitis affected 
individuals. 
For sites exhibiting the severe form of periodontitis with baseline PDs of 8 mm, 
the post-hoc intragroup analysis presented a statistically significant difference between 
the minocycline gel group and the sham group with respect to %BOP reduction at the 
nine-month time point only.  This interesting finding can be attributed to the repetitive 
effect of the application of minocycline gel throughout the study, yielding a statistically 
significant difference compared to SRP treated sites. With respect to other clinical 
variable outcomes, the minocycline gel group yielded statistically significant differences 
only when compared to the vehicle control group. These finding again show that the gel 
by itself without minocycline does not contribute to a clinical improvement. It is the 
minocycline agent then, in the gel form, in a local delivery system which presents the 
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adjunctive effect as shown in clinical outcomes (PD, CAL, %BOP) in sites with a clinical 
manifestation of moderate to severe periodontitis. 
The lack of an adjunctive benefit to moderate chronic periodontitis sites is in 
contradiction to the results of the study by Williams and his co-workers, where the 
investigators looked at the efficacy of minocycline biodegradable microspheres33,63. As 
they reported, a statistically significant pocket depth reduction of sites ≥ 5 mm at baseline 
exhibited as much as 0.24 mm additional PD reduction in minocycline microspheres 
compared to placebo (SE of 0.04). In our study, at sites ranging from 5 - ≤7 mm at 
baseline, there was a 0.28 mm additional PD reduction in minocycline gel treated sites 
compared to the sham group at 9-months. These results failed to reach the level of 
statistical significance, perhaps due to lack of power (p > 0.05). Williams reported an 
odds ratio of 1.59 and 2.86 for baseline pocket depths of ≥ 5 mm and ≥ 6 mm, 
respectively to be reduced to 4 mm. In our study, the odds ratio was 1.13 and 1.56 for 
5 - 7 mm and ≥8 mm, respectively (Data not shown). The differences in these results 
may again be attributed to the much higher power and greater number of sites in the 
Williams study (748 subjects compared to our 58 subjects). In an attempt to find the 
‘critical PD level’ indicating the clinical use of minocycline gel, statistics were performed 
for different pocket brackets for the different study groups. For PD levels of ≥5 - ≤6 mm 
and ≥7 mm (Data not shown), there was no statistically significant difference between the 
three study groups with respect to the clinical variable outcomes: PD, CAL, and BOP. 
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Other investigators have also examined the effect of subgingival, local delivery 
antibiotic formulations on subgingival bacteria81. Overall, local delivery antibiotics have 
shown positive effects not only on clinical variables, but also on the bacterial flora. Upon 
local delivery antimicrobial application, the subgingival numbers of cocci increased, and 
the percentage of pathogenic motile rods and spirochetes has been shown to decrease 
compared to baseline levels. 
Concentrations of locally delivered minocycline in the gingival crevicular fluid 
remain at clinically effective levels for at least 7-10 days. Patients receiving 100 mg of 
minocycline systemically had a gingival crevicular fluid concentration as low as 4.3 
µg/ml82. One dose of slow release local delivery minocycline can produce GCF levels of 
340 µg/ml - a much higher concentration of minocycline and much more potent than 
systemic minocycline. Minocycline MIC for bacteria associated with chronic 
inflammatory periodontal disease ranged from 0.03 to 32 µg/mL. Since systemically 
administered antibiotics cannot reach such high levels of concentration in the GCF, it is 
unlikely that these bacterial pathogens can be affected substantially enough to create a 
more clinically favorable result with respect to periodontal clinical variables in moderate 
to severe periodontitis affected sites.83.   
We did not have supportive periodontal therapy throughout the study. The clinical 
responses reported in this thesis are in agreement with other published literature, 
indicating local delivery antibiotics to be ineffective as a sole periodontal therapy. It 
would be reasonable to say that if supportive periodontal maintenance was performed in 
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this study every 3-4 months it would have enhanced the clinical response at sites 
receiving minocycline gel as an adjunct to SRP, similar to the % BOP reduction we 
reported at the 3-month time point. 
Clinical attachment was a major clinical outcome variable sought in this study as 
an important factor in determining clinical success. In both moderate and severe chronic 
periodontitis sites, there was no statistically significant CAL difference between any of 
the study groups at all time points, including the nine-month visit. According to the 
results presented in this investigation, minocycline gel as an adjunct to SRP did not 
present superior improvement in CAL gains compared to SRP alone, and it did not 
provide additional improvement to the clinical results of treated teeth. 
The literature reports a mean average of 0.8 mm additional positive CAL gain 
when local delivery antimicrobial agents are used as adjuncts to mechanical 
instrumentation84. A note should be made with respect to these finding that there was a 
statistically significant difference between the study groups at baseline with respect to 
CAL. The CAL levels of the minocycline gel group had less CAL loss than the sham 
group, so the sites which had minocycline gel had less potential for CAL gain. Although 
the intra group post-hoc analyses did not reach the level of a statistically significant 
difference between the minocycline gel group and the sham group with respect to CAL 
gain, we did have 0.54 mm of more mean CAL gain in favor of the minocycline gel 
group.  
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In this study, the clinical response to minocycline gel was not distinguished 
between molars and single rooted teeth. It is well established from the literature that 
molar teeth had an average 1.0 mm deeper probing depth than single rooted teeth in 
periodontitis patients85. Pihlstrom and colleagues, in a longitudinal study, found that 
molars with initial probing depths of 4-6 mm responded less favorably to periodontal 
therapy than single rooted teeth with similar baseline pocket depths. The differences in 
the clinical response to non-surgical periodontal therapy may be attributed to furcation 
involvement. We cannot exclude the positive nor negative effect molars had on clinical 
variable outcomes in response to the different therapies in this study.  
The assumption that all periodontitis patients are equally susceptible to 
periodontitis is no longer accurate and it is a misconception that is oversimplified. The 
paradigm that disease severity is a function of magnitude and of duration of exposure to 
bacteria is no longer completely accurate. It is becoming more and more evident that the 
idea that we can prevent and treat chronic periodontitis predictably as long as we have 
adequate bacterial control is a misconception. It is well established that adults with 
moderate to severe generalized periodontitis and individuals that are missing teeth are 
more prevalent in specific subsets of the population.  
As of today, there are several slow-release devices that deliver anti-microbial 
drugs directly into the periodontal pockets. The use of these agents, such as Atridox (high 
concentration of doxycycline), Arestin (biodegradable minocycline microspheres), and 
PerioChip (Chlorhexidine), provides a long-lasting, high concentration of the active drug 
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placed directly into the periodontally involved sites. Although these antimicrobial agents 
differ with respect to their application technique and the concentration of the drug, there 
are randomized clinical trials that have shown that their use as adjuncts to scaling and 
root planing can result in a significantly greater PD reduction and an increased average 
CAL gain (mainly in very deep PDs), thus enhancing clinical variable outcomes84.  
Whether or not to utilize local delivery antimicrobials as part of periodontal 
therapy should be weighed mainly against the strong evidence presented to date in the 
literature that supports the use of systemic antibiotics as an adjunct to non-surgical 
periodontal therapy. The dentist should also consider the adverse reactions, as well as the 
pros and cons, of adjunctive local delivery antimicrobials as an alternative to adjunctive 
systemic antibiotics. The advantages of local delivery over systemic antibiotics have been 
described previously, including: 1) better compliance; 2) an enhanced pharmacokinetic 
response; 3) advantage of placing the active agent in close proximity to a disease site and 
a lower total dose of drug at a more controlled concentration122. Despite the clinical trials 
supporting the use of local delivery antimicrobials, there are reviews and position papers 
that state the SRP and the most popular local delivery system today, minocycline 
microspheres, present only a low level of evidence to support its use with respect to the 
balance between benefits and adverse effects86,87. Despite these recommendations, we do 
know, as previously mentioned, that not all periodontitis patients should be treated the 
same with an identical protocol. Each treatment plan should be tailored on a case by case 
basis and it must be profoundly thought through. Periodontal treatment plans should take 
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into consideration the overall systemic condition and environmental effects, as well the 
financial aspects of the treatment plan. The use of local delivery adjuncts can be 
advocated and should be considered in the proper context. 
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CONCLUSIONS 
Overall, minocycline gel presented clinically a positive response for sites with moderate 
to severe forms of periodontitis. Minocycline gel as an option to treat multiple sites, with 
less chairside time and in a more application-friendly manner, makes the gel form a more 
affordable and thus more accessible method to treat periodontitis patients. In order to see 
if the results we found were an under - or an overestimation of the true efficacy of the 
minocycline in a gel form, further and larger scale studies looking into different 
periodontitis subgroups should be conducted. These subgroups can include studies of 
multi rooted teeth vs. single rooted teeth, patients with diabetes type 2, tobacco-users, and 
in clinical cases where esthetics is a concern in order to make more definitive 
recommendations. 
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Table 1. Study Timeline and Procedures Completed in the Clinical Trial. 
Procedure Visit 1 
Screening 
Visit 2 
Baseline 
Visit 3 
Evaluation 
Visit 4 
Evaluation 
Visit 5 
Evaluation 
Visit 6 
evaluation 
Visit 7 
Evaluation 
Visit 8 
Evaluation 
Day -30 to 0 Day 0 Day 4 Day 14 Month 1 Month 3 Month 6 Month 9 
Informed 
consent 
X        
Medical 
history 
X        
Oral 
examination 
X X X X X X X X 
Vital signs  X      X 
Urine pregnancy 
test (Females) 
 X    X X  
SRP  X       
Periodontal 
assessment 
 X   X X X X 
Treatment 
administration 
 X  X X X X  
Post op OHI  X  X X X X X 
Adverse effect 
recording 
 X X X X X X X 
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Table 2. Demographic Data and Tobacco-Use for Enrolled Subjects at the Screening    
               Appointment*.  
Variable Category 
Sham control 
 (n=19) 
Vehicle control 
 (n=20) 
Minocycline gel 
 (n=20) p-value 
Gender n (%)                           Male 12 (63%) 12 (60%) 10 (50%) 0.72 
 Female 7 (37%) 8 (40%) 10 (50%)  
Age at treatment mean 
years (SD) 
 51.5 (13.8) 50.8 (10.5) 53.8 (11.3) 0.71 
Race n (%)                                Caucasian 15 (79%) 19 (95%) 12 (60%) 0.09 
 Black 1 (5%) 0 (0%) 5 (25%)  
 Asian 2 (11%) 1 (5%) 2 (10%)  
 Other 1 (5%) 0 (0%) 1 (5%)  
Tobacco-use n (%)                    Non-user 6 (32%) 4 (20%) 8 (40%) 0.74 
 Ex-user 6 (32%) 8 (40%) 5 (25%)  
 Current user 7 (37%) 8 (40%) 7 (35%)  
Tobacco amount n (%)                    Light 3 (23%) 5 (31%) 3 (25%) 0.60 
 Moderate 8 (62%) 8 (50%) 9 (75%)  
 Heavy 2 (15%) 3 (19%) 0 (0%)  
Duration of tobacco-
use mean years (SD) 
 19.8 (14.2) 20.0 (13.9) 22.0 (12.8) 0.90 
* Summaries shown are mean (standard deviation) or n (percent). 
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Table 3. Mean Clinical Variables for sites evaluated of all Subjects at Baseline in the  
               Three Study Groups*.  
Variable 
Sham control 
 (n=19) 
Vehicle control 
 (n=20) 
Minocycline gel 
 (n=19) p-value 
Pocket depth (PD) 5.82 (0.13) 5.65 (0.08) 5.68 (0.09) 0.45 
Clinical attachment 
level (CAL) 5.33 (0.25) 4.79 (0.22) 4.87 (0.26) 0.24 
Percent bleeding on 
probing (BOP) 92.51 (2.57) 95.71 (1.31) 95.46 (1.48) 0.41 
* Summaries shown are mean (standard error) 
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Table 4. Mean Clinical Variable for Sites Evaluated of all Subjects and Changes in  
               Clinical Variables from Baseline at 3-months from *. 
 
Variable 
Sham control 
 (n=19) 
Vehicle control 
 (n=20) 
Minocycline gel 
 (n=19) p-value 
Pocket depth       4.30 (0.14) 4.15 (0.14) 4.07 (0.14) 0.49 
Pocket depth reduction 
from baseline 1.51 (0.14) 1.50 (0.11) 1.60 (0.14) 0.84 
Clinical attachment level 3.85 (0.28) 3.46 (0.25) 3.47 (0.24) 0.48 
Clinical attachment gain 
from baseline  1.48 (0.18) 1.33 (0.11) 1.40 (0.14) 0.77 
%BOP                      
53.77 (5.34) 44.37 (5.99) 37.27 (6.15) 0.15 
%BOP reduction from 
baseline 
39.74 (3.96) 51.34 (5.91) 58.19 (5.84) 0.04** 
Percent of sites PDs 
improved by 2 mm 44.17 (4.75) 50.57 (4.59) 53.23 (4.21) 0.36 
Percent of sites PDs  
improved by 3 mm 19.29 (4.12) 16.73 (3) 17.61 (3.94) 0.88 
* Summaries shown are mean (standard error).  
** Statistically significant (P<0.05) 
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Table 5.  Mean Clinical Variable for evaluated sites of all Subjects and Changes in  
                Clinical Variables from Baseline at 6-months from *.           
Variable 
Sham control 
 (n=18) 
Vehicle control 
 (n=19) 
Minocycline gel 
 (n=19) p-value 
Pocket depth       4.27 (0.17) 4.19 (0.16) 3.99 (0.13) 0.41 
Pocket depth reduction 
from baseline 1.52 (0.14) 1.49 (0.12) 1.69 (0.13) 0.51 
Clinical attachment level  3.86 (0.28) 3.48 (0.25) 3.51 (0.26) 0.54 
Clinical attachment gain 
from baseline  1.37 (0.09) 1.31 (0.08) 1.36 (0.12) 0.91 
%BOP                      41.27 (4.60) 46.06 (4.83) 37.15 (5.44) 0.45 
%BOP reduction from 
baseline 51.24 (3.61) 49.65 (4.72) 58.31 (5.67) 0.38 
Percent of sites PDs 
improved by 2 mm 45.50 (5.40) 48.84 (5.68) 53.73 (4.91) 0.55 
Percent of sites PDs 
improved by 3 mm 16.33 (3.77) 18.03 (2.60) 21.61 (4.14) 0.57 
* Summaries shown are mean (standard error). 
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Table 6. Mean Clinical Variables for sites evaluated of all Subjects and Changes in  
               Clinical Variables from Baseline at 9-months from*. 
Variable 
Sham control 
 (n=17) 
Vehicle control 
 (n=18) 
Minocycline gel 
 (n=19) p-value 
Pocket depth       4.29 (0.18) 3.96 (0.16) 3.91 (0.13) 0.20 
Pocket depth reduction 
from baseline 1.45 (0.13) 1.72 (0.14) 1.76 (0.14) 0.24 
Clinical attachment level  3.94 (0.31) 3.18 (0.30) 3.32 (0.26) 0.17 
Clinical attachment gain 
from baseline  1.28 (0.10) 1.56 (0.13) 1.56 (0.12) 0.19 
%BOP                      40.84 (5.28) 49.63 (4.57) 32.50 (3.71) 0.03** 
%BOP reduction from 
baseline 51.67 (4.20) 46.08 (4.98) 62.96 (3.94) 0.03** 
Percent of sites PDs 
improved by 2 mm 45.37 (4.50) 57.95 (5.38) 57.19 (5.21) 0.16 
Percent of sites PDs 
improved by 3 mm 15.32 (3.60) 22.95 (4.45) 22.60 (4.19) 0.35 
* Summaries shown are mean (standard error).  
** Statistically significant (P<0.05) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
54 
 
Table 7. Mean Clinical Variable for Sites Evaluated of all Subjects at baseline for patients with  
                PDs 5-≤7 mm*. 
Variable 
Sham control 
 (n=19) 
Vehicle control 
 (n=20) 
Minocycline gel 
 (n=19) p-value 
Pocket depth 5.59 (0.08) 5.52 (0.05) 5.52 (0.06) 0.66 
Clinical attachment 
level 5.10 (0.24) 4.68 (0.21) 4.73 (0.24) 0.38 
%BOP 93.02 (2.63) 95.92 (1.28) 95.20 (1.55) 0.53 
* The data was aggregated at the patient level by averaging across the outcomes for all  
   sites with a pocket depth of 5-7 mm at baseline. Summaries shown are mean (standard    
   error). 
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Table 8. Mean Clinical Variable for Sites Evaluated of all Subjects and Changes in  
               Clinical Variables from Baseline at 3-months for patients with PDs 5-≤7 mm*.  
Variable 
Sham control 
 (n=19) 
Vehicle control 
 (n=20) 
Minocycline gel 
(n=19) p-value 
Pocket depth       
4.19 (0.12) 4.07 (0.14) 3.99 (0.13) 0.54 
Pocket depth reduction 
from baseline 1.40 (0.13) 1.45 (0.11) 1.53 (0.13) 0.77 
Clinical attachment level  
3.75 (0.29) 3.38 (0.26) 3.38 (0.23) 0.52 
Clinical attachment gain 
from baseline  1.35 (0.15) 1.30 (0.11) 1.36 (0.13) 0.95 
%BOP                      
52.23 (5.45) 43.14 (6.03) 36.86 (6.01) 0.19 
%BOP reduction from 
baseline 52.18 (4.09) 47.29 (5.99) 62.7 (5.71) 0.07 
Percent of sites PDs 
improved by 2 mm 42.46 (4.79) 49.41 (4.64) 51.82 (4.19) 0.33 
Percent of sites PDs 
improved by 3 mm 17.47 (3.97) 16.19 (2.92) 15.30 (3.81) 0.91 
* The data was aggregated at the patient level by averaging across the outcomes for all  
   sites with a pocket depth of 5-7 mm at baseline. Summaries shown are mean  
   (standard error). 
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Table 9. Mean Clinical Variable for Sites Evaluated of all Subjects and Changes in  
              Clinical Variables from Baseline at 6-months for patients with PDs 5-≤7 mm *.  
Variable 
Sham control  
(n=18) 
Vehicle control 
 (n=19) 
Minocycline gel 
 (n=19) p-value 
Pocket depth       4.16 (0.14) 4.10 (0.15) 3.90 (0.13) 0.39 
Pocket depth reduction 
from baseline 1.43 (0.13) 1.44 (0.13) 1.62 (0.13) 0.51 
Clinical attachment level 3.75 (0.29) 3.40 (0.25) 3.43 (0.26) 0.59 
Clinical attachment gain 
from baseline  1.29 (0.08) 1.29 (0.08) 1.30 (0.13) 0.99 
%BOP                      39.56 (4.81) 44.48 (4.67) 36.25 (5.55) 0.51 
%BOP reduction from 
baseline 53.46 (3.74) 51.44 (4.45) 58.95 (5.78) 0.49 
Percent of sites PDs 
improved by 2 mm 44.71 (5.33) 46.86 (5.98) 52.67 (4.95) 0.57 
Percent of sites PDs 
improved by 3 mm 15.17 (3.60) 17.36 (2.79) 18.66 (3.99) 0.78 
* The data was aggregated at the patient level by averaging across the outcomes for all  
   sites with a pocket depth of ≥5-≤7 mm at baseline. Summaries shown are mean    
   (standard error). 
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Table 10. Mean Clinical Variable for Sites Evaluated of all Subjects and Changes in  
              Clinical Variables from Baseline at 9-months for patients with PDs 5-≤7 mm *.  
Variable 
Sham control 
 (n=17) 
Vehicle control 
 (n=18) 
Minocycline gel 
 (n=19) p-value 
Pocket depth       4.17 (0.15) 3.86 (0.15) 3.83 (0.12) 0.19 
Pocket depth reduction from 
baseline 1.37 (0.13) 1.69 (0.14) 1.69 (0.14) 0.19 
Clinical attachment level  3.84 (0.32) 3.09 (0.30) 3.23 (0.25) 0.17 
Clinical attachment gain 
from baseline  1.21 (0.10) 1.56 (0.13) 1.50 (0.13) 0.10 
%BOP                      39.39 (5.29) 48.25 (4.69) 32.35 (3.77) 0.06 
%BOP reduction from 
baseline 53.63 (4.09) 47.67 (5.12) 62.85 (4.06) 0.06 
Percent of sites PDs 
improved by 2 mm 44.17 (4.53) 57.17 (5.34) 55.66 (5.25) 0.16 
Percent of sites PDs 
improved by 3 mm 14.40 (3.48) 22.70 (4.54) 20.25 (4.16) 0.36 
* The data was aggregated at the patient level by averaging across the outcomes for all  
   sites with a pocket depth of 5-7 mm at baseline. Summaries shown are mean 
(standard  
   error). 
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Table 11. Demographics and Tobacco-Use for patients in the three study groups with  
     PDs ≥8 mm at baseline*.  
Variable Category 
Sham control 
 (n=10) 
Vehicle control 
 (n=10) 
Minocycline gel 
 (n=13) p-value 
Gender n (%)                        Male 7 (70%) 7 (70%) 7 (54%) 0.73 
 Female 3 (30%) 3 (30%) 6 (46%)  
Age at treatment 
mean years (SD) 
 51.6 (11.8) 51.9 (12.3) 52.6 (10.1) 0.98 
Race n (%)                                 Caucasian 9 (90%) 9 (90%) 6 (46%) 0.12 
 Black 1 (10%) 0 (0%) 4 (31%)  
 Asian 0 (0%) 1 (10%) 2 (15%)  
 Other 0 (0%) 0 (0%) 1 (8%)  
Tobacco-use n (%)                        Non-user 3 (30%) 3 (30%) 5 (38%) >0.99 
 Ex-user 3 (30%) 3 (30%) 3 (23%)  
 Current 
user 
4 (40%) 4 (40%) 5 (38%)  
Duration of tobacco-
use mean years (SD) 
 16.9 (11.8) 24.1 (14.1) 21.4 (13.3) 0.59 
* Summaries shown are mean (standard deviation) or n (percent). 
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Table 12. Mean Clinical Variables for sites evaluated of all Subjects with PDs ≥8 mm at  
                 Baseline*. 
Variable 
Sham control 
 (N=10) 
Vehicle control 
 (N=10) 
Minocycline gel 
 (N=13) P-value 
Pocket depth 8.38 (0.13) 8.09 (0.05) 8.15 (0.08) 0.08 
Clinical attachment 
level 
8.06 (0.27) 6.71 (0.45) 7.02 (0.36) 0.05** 
%BOP                      
86.25 (6.57) 89.17 (5.83) 100 (0.00) 0.09 
* The data was aggregated at the patient level by averaging across the outcomes for all     
   sites with a pocket depth of ≥8 mm at baseline. Summaries shown are mean (standard  
   error). For variables having significant group differences, p-values from post-hoc tests  
   for pairwise group comparisons are shown in Table 17. 
** Statistically significant (P<0.05) 
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Table 13. Mean Clinical Variables for Sites Evaluated of all Subjects and Changes in  
                Clinical Variables at 3-Months from Baseline for Patients with PDs ≥8 mm*.  
Variable 
Sham control 
 (n=9) 
Vehicle control 
 (n=10) 
Minocycline gel 
 (n=13) p-value 
Pocket depth  5.68 (0.51) 5.88 (0.51) 5.28 (0.37) 0.62 
Pocket depth reduction 
from baseline) 
2.64 (0.47) 2.21 (0.53) 2.87 (0.39) 0.58 
Clinical attachment level  
5.48 (0.41) 5.02 (0.70) 4.96 (0.47) 0.77 
Clinical attachment gain 
from baseline  2.41 (0.53) 1.69 (0.53) 2.07 (0.36) 0.58 
%BOP  
58.87 (12.36) 66.67 (12.91) 54.12 (11.56) 0.76 
%BOP reduction from 
baseline  
27.38 (14.13) 22.50 (10.83) 45.88 (11.56) 0.37 
Percent of sites PDs 
improved by 2 mm  63.25 (11.85) 57.74 (13.57) 77.75 (8.73) 0.41 
Percent of sites PDs 
improved by 3 mm  47.46 (10.97) 25.71 (11.38) 54.12 (10.85) 0.19 
* The data was aggregated at the patient level by averaging across the outcomes for all  
   sites with a pocket depth of ≥8 mm at baseline. Summaries shown are mean (standard  
   error). 
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Table 14. Mean Clinical Variable for Sites Evaluated of all Subjects and Changes in  
                 Clinical Variables at 6-Months from Baseline for Patients with PDs ≥8 mm *.  
Variable 
Sham control 
 (n=8) 
Vehicle control 
 (n=10) 
Minocycline gel 
 (n=13) p-value 
Pocket depth  5.74 (0.63) 6.15 (0.32) 5.24 (0.34) 0.28 
Pocket depth reduction from 
baseline 2.61 (0.56) 1.94 (0.35) 2.91 (0.28) 0.17 
Clinical attachment level 
5.39 (0.54) 5.08 (0.46) 4.65 (0.43) 0.54 
Clinical attachment gain 
from baseline 2.32 (0.47) 1.63 (0.39) 2.38 (0.27) 0.28 
%BOP  
47.46 (13.98) 72.14 (10.83) 40.93 (9.68) 0.12 
%BOP reduction from 
baseline 
38.79 (17.66) 17.03 (11.62) 59.07 (9.68) 0.06 
Percent of sites PDs 
improved by 2 mm 69.32 (12.56) 64.40 (12.95) 76.65 (8.72) 0.71 
Percent of sites PDs 
improved by 3 mm 40.07 (14.14) 30.36 (11.66) 71.70 (8.79) 0.02** 
* The data was aggregated at the patient level by averaging across the outcomes for all  
   sites with a pocket depth of ≥8 mm at baseline. Summaries shown are mean (standard  
   error). 
** Statistically significant (p<0.05) 
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Table 15. Mean Clinical Variable for Sites Evaluated of all Subjects and Changes in  
                 Clinical Variables at 9-Months from Baseline for Patients with PDs ≥8 mm *.  
Variable 
Sham control 
 (n=7) 
Vehicle control 
 (n=9) 
Minocycline gel 
 (n=13) 
p-
value 
Pocket depth  5.99 (0.45) 6.19 (0.32) 4.87 (0.35) 0.03** 
Pocket depth reduction from 
baseline 2.34 (0.41) 1.88 (0.34) 3.27 (0.36) 0.03** 
Clinical attachment level 
5.60 (0.38) 5.11 (0.59) 4.31 (0.56) 0.28 
Clinical attachment gain 
from baseline  2.18 (0.37) 1.35 (0.32) 2.71 (0.30) 0.01** 
%BOP 
73.95 (8.23) 68.78 (13.77) 36.81 (9.62) 0.04** 
%BOP reduction from 
baseline,  
12.30 (8.22) 20.39 (11.47) 63.19 (9.62) 0.05** 
Percent of sites PDs 
improved by 2 mm 75.13 (11.06) 59.79 (13.11) 89.29 (6.62) 0.10 
Percent of sites PDs 
improved by 3 mm 33.80 (14.19) 21.43 (8.94) 62.91 (10.89) 0.03** 
* The data was aggregated at the patient level by averaging across the outcomes for all  
   sites with a pocket depth of ≥8 mm at baseline. Summaries shown are mean (standard  
   error). 
** Statistically significant (P<0.05) 
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Table 16. p-values for Intragroup analysis for statistically significant findings of the  
     Various Clinical Variables and Clinical Variables Change*. 
Variable Group Timing 
Sham Control 
 vs.  
vehicle control 
Minocycline gel 
vs.   
Sham Control  
 
Minocycline gel 
vs.  
Vehicle control 
Percent bleeding on 
probing reduction from 
baseline All patients 3 months 0.22 0.03** 0.64 
%BOP                      
All patients 9 months 0.37 0.40 0.02** 
%BOP reduction from 
baseline 
All patients 9 months 0.61 0.21 0.02** 
Clinical attachment 
level Sites of 8 mm Baseline 0.06 0.13 0.82 
Percent of sites 
improved by 2 mm Sites of 8 mm 6 months 0.83 0.14 0.02** 
Pocket depth       Sites of 8 mm 9 months 0.94 0.12 0.03** 
Pocket depth reduction 
from baseline Sites of 8 mm 9 months 0.72 0.23 0.03** 
Clinical attachment 
gain from baseline  Sites of 8 mm 9 months 0.26 0.51 0.01** 
Percent bleeding on 
probing                      Sites of 8 mm 9 months 0.95 0.07 0.10 
Percent bleeding on 
probing reduction from 
baseline 
Sites of 8 mm 9 months 0.95 0.01** 0.01** 
Percent of sites 
improved by 3 mm Sites of 8 mm 9 months 0.77 0.21 0.03** 
* p-values from post -hoc tests for pairwise group comparisons for variables for which  
   the overall group comparisons were statistically significant. 
** Statistically significant (P<0.05) 
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